Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.35 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.35 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006311 | 0.83 | AADAT (0.34) | — | |
| SCHEMBL12006571 | 0.76 | PIK3CA (0.32) | — | |
| SCHEMBL12005011 | 0.71 | ABL1 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ABL1 | |
| SCHEMBL12006296 | 0.71 | ABL1 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ABL1 | |
| SCHEMBL12005013 | 0.71 | ABL1 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ABL1 | |
| SCHEMBL12005399 | 0.70 | PIK3CB (0.53) | — | |
| SCHEMBL12006558 | 0.68 | PIK3CA (0.36) | — | |
| SCHEMBL13733902 | 0.65 | P2RX7 (0.42) | ABL1BCR | |
| SCHEMBL12005646 | 0.64 | MTOR (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1ABL1 | |
| SCHEMBL12005612 | 0.63 | ABL1 (0.39) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | GUCY1B2 750/4885GUCY1A2 1644/4885GUCY1A1 824/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | GUCY1B2 750/4885GUCY1A2 1644/4885GUCY1A1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.